These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26900365)

  • 21. Corrigendum to "Dose painting by numbers based on retrospectively determined recurrence probabilities" [Radiother Oncol 122 (2017) 236-241].
    Grönlund E; Johansson S; Montelius A; Ahnesjö A
    Radiother Oncol; 2019 Feb; 131():243. PubMed ID: 30563693
    [No Abstract]   [Full Text] [Related]  

  • 22. Corrigendum to "A case-control study to identify molecular risk factors for local recurrence in young breast cancer patients" [Radiother Oncol 156 (2021) 127-135].
    Bosma SCJ; Hoogstraat M; van Werkhoven E; de Maaker M; van der Leij F; Elkhuizen PHM; Fourquet A; Poortmans P; Boersma LJ; Bartelink H; van de Vijver MJ;
    Radiother Oncol; 2021 Oct; 163():244. PubMed ID: 34120786
    [No Abstract]   [Full Text] [Related]  

  • 23. Corrigendum to "Local control and postponement of systemic therapy after modest dose radiotherapy in oligometastatic myxoid liposarcomas" [Radiother. Oncol. 158 (2021) 33-39].
    Lansu J; van Houdt WJ; van Langevelde K; van den Ende PLA; van der Graaf WTA; Schrage Y; van Boven H; Scholten AN; Haas RL
    Radiother Oncol; 2021 Oct; 163():245. PubMed ID: 34243980
    [No Abstract]   [Full Text] [Related]  

  • 24. Corrigendum to "Similar long-term swallowing outcomes for accelerated, mildly-hypofractionated radiotherapy compared to conventional fractionation in oropharynx cancer: A multi-centre study" [Radiother. Oncol. 172 (2022) 111-117].
    Price JM; West CM; Dixon LM; Iyizoba-Ebozue Z; Garcez K; Lee LW; McPartlin A; Williams G; Slevin F; Sykes A; Prestwich RJD; Thomson DJ
    Radiother Oncol; 2022 Dec; 177():163. PubMed ID: 36395551
    [No Abstract]   [Full Text] [Related]  

  • 25. Corrigendum to "Master protocol trial design for technical feasibility of MR-guided radiotherapy" [Radiother. Oncol. 166 (2022) 33-36].
    Couwenberg A; Van der Heide U; Janssen T; Van Triest B; Remeijer P; Marijnen C; Sonke JJ; Nowee M
    Radiother Oncol; 2023 Jul; 184():109693. PubMed ID: 37207559
    [No Abstract]   [Full Text] [Related]  

  • 26. Corrigendum to "Safety and feasibility of CDK4/6 inhibitors treatment combined with radiotherapy in patients with HR-positive/HER2-negative breast cancer. A systematic review and meta-analysis" [Radiother. Oncol. 187 (2023) 109839].
    Kubeczko M; Jarząb M; Gabryś D; Krzywon A; Cortez AJ; Xu AJ
    Radiother Oncol; 2024 May; 194():110188. PubMed ID: 38447357
    [No Abstract]   [Full Text] [Related]  

  • 27. Corrigendum to "Harmonization of breast cancer radiotherapy treatment planning in the Netherlands" [Tech. Innov. Patient Support Radiat. Oncol. 19 (2021) 26-32].
    Hurkmans C; Duisters C; Peters-Verhoeven M; Boersma L; Verhoeven K; Bijker N; Crama K; Nuver T; van der Sangen M
    Tech Innov Patient Support Radiat Oncol; 2023 Mar; 25():100196. PubMed ID: 36659912
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Corrigendum to "Interaction between CIEDs and modern radiotherapy techniques: Flattening filter free-VMAT, dose-rate effects, scatter radiation, and neutron-generating energies" [Radiother Oncol 152 (2020) 196-202].
    Gauter-Fleckenstein B; Nguyen J; Jahnke L; Gaiser T; Rudic B; Büttner S; Wenz F; Borggrefe M; Tülümen E
    Radiother Oncol; 2021 Jan; 154():291. PubMed ID: 33460982
    [No Abstract]   [Full Text] [Related]  

  • 29. Corrigendum to "Measurement of circulating free DNA in squamous cell carcinoma of the anus and relation to risk factors and recurrence" [Radiother. Oncol. 150 (2020) 211-216].
    Lefèvre AC; Kronborg C; Sørensen BS; Krag SRP; Serup-Hansen E; Spindler KG
    Radiother Oncol; 2021 Jul; 160():228. PubMed ID: 34052746
    [No Abstract]   [Full Text] [Related]  

  • 30. Set-up error in supine-positioned patients immobilized with two different modalities during conformal radiotherapy of prostate cancer.
    Fiorino C; Reni M; Bolognesi A; Bonini A; Cattaneo GM; Calandrino R
    Radiother Oncol; 1998 Nov; 49(2):133-41. PubMed ID: 10052878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
    Obata H; Shiota M; Akitake N; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
    Anticancer Res; 2017 Oct; 37(10):5631-5637. PubMed ID: 28982880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Corrigendum to "Surface-guided radiotherapy for lung cancer can reduce the number of close patient contacts without compromising initial setup accuracy" [Tech. Innov. Patient Support Radiat. Oncol. 20 (2021) 61-63].
    Blake N; Pereira L; Eaton DJ; Dobson D
    Tech Innov Patient Support Radiat Oncol; 2023 Mar; 25():100197. PubMed ID: 36659911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Corrigendum to: "Nuclear EGFR as a molecular target in cancer" [Radiother Oncol 108 (2013) 370-77].
    Brand TM; Iida M; Luthar N; Starr MM; Huppert EJ; Wheeler DL
    Radiother Oncol; 2019 Jan; 130():195. PubMed ID: 30442378
    [No Abstract]   [Full Text] [Related]  

  • 34. Prognostic factors after salvage radiotherapy alone in patients with biochemical recurrence after radical prostatectomy.
    Song W; Jeon HG; Sung HH; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM
    Int J Urol; 2016 Jan; 23(1):56-61. PubMed ID: 26502086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Corrigendum to "Evaluation of a whole process management model based on an information system for cancer patients with pain: A prospective nonrandomized controlled study" [Asia-Pacific J Oncol Nurs 9 (2022) 88-96].
    Yang H; Yu W; Zhang H; Heng F; Ma X; Li N; Wang Z; Hou X; Guo R; Lu Y
    Asia Pac J Oncol Nurs; 2023 Mar; 10(3):100192. PubMed ID: 36876163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.
    Savdie R; Horvath LG; Benito RP; Rasiah KK; Haynes AM; Chatfield M; Stricker PD; Turner JJ; Delprado W; Henshall SM; Sutherland RL; Kench JG
    BJU Int; 2012 Jun; 109(12):1794-800. PubMed ID: 21992536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy.
    Do T; Parker RG; Do C; Tran L; Do L; Dolkar D
    Cancer J Sci Am; 1998; 4(5):324-30. PubMed ID: 9815297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Corrigendum to: "BMI1-KLF4 axis deficiency improves responses to neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer" [Radiother Oncol 149 (2020) 249-258].
    Hsu YC; Luo CW; Huang WL; Wu CC; Chou CL; Chen CI; Chang SJ; Chai CY; Wang HC; Chen TY; Li CF; Pan MR
    Radiother Oncol; 2021 Oct; 163():247-248. PubMed ID: 34344522
    [No Abstract]   [Full Text] [Related]  

  • 39. Corrigendum to "Detecting Clostridioides (Clostridium) difficile using canine teams: What does the nose know?" [Infect Prev Pract 1 (2019) 100005].
    Charles MK; Wang Y; Zurberg T; Kinna J; Bryce E
    Infect Prev Pract; 2020 Sep; 2(3):100087. PubMed ID: 34374703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Corrigendum to "Catheter-related bloodstream infection caused by
    Hou C
    Infect Prev Pract; 2020 Sep; 2(3):100088. PubMed ID: 34374693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.